Inotek Pharma (ITEK) Reports Q1 Loss of $0.38
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/29/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
Inotek Pharmaceuticals Corporation Reports First Quarter 2016 Financial Results and Operational Highlights
May 11, 2016 7:00 AM EDTLEXINGTON, Mass.--(BUSINESS WIRE)-- Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today reported financial results and operational highlights for the quarter ended March 31, 2016.
The Phase 3 MATrX-1 study of trabodenoson continues to enroll well, and we continue to expect top-line data from this... More
